AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28275127 — intervention group
Group type: COMPARATOR
Intervention: Control (ad libitum consumption)
Number of subjects: 39
Study 26227186 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin plus ezetimibe (10 mg) daily
Number of subjects: 202
Study 26227186 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 202
Study 24079283 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3750 mg/d) with niacin titration
Number of subjects: 140
Study 24079283 — intervention group
Group type: COMPARATOR
Intervention: Placebo with niacin titration
Number of subjects: 140
Study 21133824 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg allopurinol daily for 12 weeks
Number of subjects: 100
Study 21133824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18947826 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver yoga exercises (70-min sessions, three times per week for 6 months)
Number of subjects: 128
Study 18947826 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 128
Study 16776701 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush allodynia (BA) tested by cutaneous stimulation with a gauze pad
Number of subjects: 55
Study 16776701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure allodynia (PA) tested using von Frey hairs (VFH)
Number of subjects: 55
Study 16776701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BA and PA
Number of subjects: 55
Study 15342305 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 675 mg/day
Number of subjects: 293
Study 15342305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 15342305 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (both doses)
Number of subjects: 293
Study 10944838 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved stoves
Number of subjects: 0
Study 10944838 — intervention group
Group type: COMPARATOR
Intervention: Traditional three-stone stoves
Number of subjects: 0
Study 9067719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonohysterosalpingography (sono-HSG) utilizing Albunex
Number of subjects: 0
Study 9067719 — intervention group
Group type: COMPARATOR
Intervention: X-ray hysterosalpingography (HSG) with standard X-ray contrast media
Number of subjects: 0
Study 8377337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (TPA)
Number of subjects: 80
Study 8377337 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 80
Study 3780128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 36
Study 3780128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 36
Study 3780128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg
Number of subjects: 36
Study 31569905 — intervention group
Group type: COMPARATOR
Intervention: Commercial vinegars
Number of subjects: 18
Study 31569905 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade vinegars
Number of subjects: 18
Study 29926514 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL-1401O
Number of subjects: 132
Study 29926514 — intervention group
Group type: COMPARATOR
Intervention: EU-trastuzumab
Number of subjects: 132
Study 29926514 — intervention group
Group type: COMPARATOR
Intervention: US-trastuzumab
Number of subjects: 132
Study 26952681 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized patient education and emotional support over six weeks.
Number of subjects: 50
Study 26952681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no individualized patient education and emotional support).
Number of subjects: 50
Study 25332478 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei DG (24 billion viable cells daily for 4 weeks)
Number of subjects: 0
Study 22054033 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Poligrip® Free (cream)
Number of subjects: 36
Study 22054033 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Poligrip® Comfort Seal Strips (strip)
Number of subjects: 36
Study 22054033 — intervention group
Group type: EXPERIMENTAL
Intervention: GlaxoSmith Kline Consumer Healthcare (cream)
Number of subjects: 36
Study 22054033 — intervention group
Group type: COMPARATOR
Intervention: No adhesive (negative control)
Number of subjects: 36
Study 22054033 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture adhesives (all types)
Number of subjects: 36
Study 22054033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream adhesives
Number of subjects: 36
Study 21111868 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE)
Number of subjects: 33
Study 18573702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free mesh repair (Lichtenstein technique)
Number of subjects: 54
Study 18573702 — intervention group
Group type: COMPARATOR
Intervention: Bassini technique
Number of subjects: 54
Study 16094791 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture notes combined with structured group discussion (experimental group)
Number of subjects: 169
Study 16094791 — intervention group
Group type: COMPARATOR
Intervention: Lecture only (control group)
Number of subjects: 169
Study 11837527 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy interventions
Number of subjects: 0
Study 11837527 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9651905 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT-group: Sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate + vitamin D3 300 IU/day + calcium lactate 500 mg/day (n = 31)
Number of subjects: 64
Study 9651905 — intervention group
Group type: COMPARATOR
Intervention: non-HRT-group: Calcium lactate 500 mg/day + vitamin D3 300 IU/day (n = 33)
Number of subjects: 64
Study 7898842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 2.5 mg of PGE2 gel every hour
Number of subjects: 101
Study 7898842 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal 2.5 mg of PGE2 gel every 6 hours
Number of subjects: 101
Study 2655717 — intervention group
Group type: EXPERIMENTAL
Intervention: Timiperone 1 mg, 3 mg, 6 mg
Number of subjects: 0
Study 2655717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 100 mg, 300 mg, 600 mg
Number of subjects: 0
Study 2655717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2655717 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol and Propericiazine (retrospective control)
Number of subjects: 0
Study 792642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (1 mg)
Number of subjects: 0
Study 792642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 792642 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0
Study 792642 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenaline
Number of subjects: 0
Study 792642 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 0
Study 30745314 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 100
Study 30745314 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 100
Study 30896248 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced website
Number of subjects: 350
Study 30896248 — intervention group
Group type: COMPARATOR
Intervention: Standard website
Number of subjects: 350
Study 28835659 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (3-day course)
Number of subjects: 120
Study 28835659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26223721 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Merocel packing
Number of subjects: 60
Study 26223721 — intervention group
Group type: COMPARATOR
Intervention: Internal nasal splint
Number of subjects: 60
Study 23948601 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic oxytocin during labour
Number of subjects: 316
Study 21785382 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (2 watts, 2‐ to 3‐mm depth, cut‐coagulating mode)
Number of subjects: 100
Study 21785382 — intervention group
Group type: COMPARATOR
Intervention: Argon laser (spot size 50 μm, 760 mW, 930‐nm wavelengths, continuous)
Number of subjects: 100
Study 21785382 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Number of subjects: 100
Study 19114891 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 108
Study 19114891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 16719881 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 66
Study 16719881 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 66
Study 15261713 — intervention group
Group type: EXPERIMENTAL
Intervention: Rater Applied Performance Scale (RAPS)
Number of subjects: 20
Study 11318574 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 600 mg
Number of subjects: 1186
Study 11318574 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole 600 mg (2 doses per year)
Number of subjects: 1186
Study 11318574 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole 600 mg (3 doses per year)
Number of subjects: 1186
Study 9510443 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (recombinant GH 0.1 IU/kg/day)
Number of subjects: 29
Study 9510443 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 29
Study 7802195 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 45
Study 7802195 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 45
Study 7802195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3124593 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat intake (450 mg.kg‐1.d‐1) at 60 kcal.kg‐1.d‐1
Number of subjects: 16
Study 3124593 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat intake (450 mg.kg‐1.d‐1) at 60 kcal.kg‐1.d‐1
Number of subjects: 16
Study 3124593 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat intake (450 mg.kg‐1.d‐1) at 80 kcal.kg‐1.d‐1
Number of subjects: 16
Study 3124593 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat intake (450 mg.kg‐1.d‐1) at 80 kcal.kg‐1.d‐1
Number of subjects: 16
Study 3124593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous energy intake ranging from 60 to 80 kcal.kg‐1.d‐1
Number of subjects: 16
Study 30589391 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB 2-week (3g/day)
Number of subjects: 28
Study 30589391 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB 4-week (3g/day)
Number of subjects: 28
Study 30589391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 28
Study 29501590 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 3 mg
Number of subjects: 0
Study 29501590 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 0
Study 29501590 — intervention group
Group type: COMPARATOR
Intervention: Macitentan (3 mg and 10 mg)
Number of subjects: 0
Study 26799247 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 48
Study 26799247 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo patches
Number of subjects: 48
Study 26799247 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking (20 cigarettes/day)
Number of subjects: 48
Study 26799247 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 48
Study 24755123 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg with 500 mg, 850 mg, or 1,000 mg metformin (FDC)
Number of subjects: 287
Study 24755123 — intervention group
Group type: COMPARATOR
Intervention: Individual tablets of linagliptin and metformin (FP)
Number of subjects: 287
Study 22404601 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in kidney paired donation (KPD)
Number of subjects: 845
Study 22404601 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences with medical or organ transplant systems
Number of subjects: 845
Study 22404601 — intervention group
Group type: COMPARATOR
Intervention: Increased age, male sex, African American race, Hispanic ethnicity, distrust of the medical system, and not understanding organ allocation
Number of subjects: 845
Study 20854564 — intervention group
Group type: EXPERIMENTAL
Intervention: LiFE programme (balance and strength training embedded in daily life)
Number of subjects: 34
Study 20854564 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 34
Study 20854564 — intervention group
Group type: EXPERIMENTAL
Intervention: LiFE programme
Number of subjects: 34
Study 17619862 — intervention group
Group type: EXPERIMENTAL
Intervention: Information emphasizing patch benefits (n = 25)
Number of subjects: 72
Study 17619862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-dose instructions (n = 25)
Number of subjects: 72
Study 17619862 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 22)
Number of subjects: 72
Study 16302595 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental program (intervention group)
Number of subjects: 30
Study 16302595 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who had never been to a dental office)
Number of subjects: 30
Study 11838629 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 384
Study 11838629 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day
Number of subjects: 384
Study 11838629 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 60 mg/day
Number of subjects: 384
Study 11838629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 10023508 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan 6 g per day
Number of subjects: 37
Study 10023508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7479300 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (50 micrograms)
Number of subjects: 12
Study 7479300 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIF (100 micrograms)
Number of subjects: 12
Study 7479300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 12
Study 2263578 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized smoking cessation counseling during periodic health examination
Number of subjects: 0
Study 2263578 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 373085 — intervention group
Group type: EXPERIMENTAL
Intervention: tolfenamic acid (100 mg 3 times daily)
Number of subjects: 33
Study 373085 — intervention group
Group type: COMPARATOR
Intervention: phenylbutazone (100 mg 3 times daily)
Number of subjects: 33
Study 7113925 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader-directed overcorrection group (A)
Number of subjects: 0
Study 7113925 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader-participative overcorrection group (P)
Number of subjects: 0
Study 7113925 — intervention group
Group type: COMPARATOR
Intervention: Standard daily safety lecture group (S)
Number of subjects: 0
Study 31903520 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 960
Study 31903520 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated female students
Number of subjects: 960
Study 31903520 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade clinical students
Number of subjects: 960
Study 31903520 — intervention group
Group type: COMPARATOR
Intervention: Nonmedical students
Number of subjects: 960
Study 31903520 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated family members or friends
Number of subjects: 960
Study 31725612 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifying narrow-band imaging (M-NBI)
Number of subjects: 163
Study 31725612 — intervention group
Group type: COMPARATOR
Intervention: Conventional white light (WL) endoscopy
Number of subjects: 163
Study 31725612 — intervention group
Group type: EXPERIMENTAL
Intervention: M-NBI
Number of subjects: 163
Study 28278010 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian 530 mg capsule twice per day for two months
Number of subjects: 60
Study 28278010 — intervention group
Group type: COMPARATOR
Intervention: Placebo 530 mg capsule (starch)
Number of subjects: 60
Study 26915963 — intervention group
Group type: EXPERIMENTAL
Intervention: Need supportive (NS) SMS sent twice weekly for 10 weeks
Number of subjects: 65
Study 26915963 — intervention group
Group type: EXPERIMENTAL
Intervention: Need supportive (NS) SMS
Number of subjects: 65
Study 26915963 — intervention group
Group type: COMPARATOR
Intervention: Neutral SMS
Number of subjects: 65
Study 24914136 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (transfusions/chelation)
Number of subjects: 0
Study 24914136 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment (hydroxyurea/phlebotomy)
Number of subjects: 0
Study 21761190 — intervention group
Group type: EXPERIMENTAL
Intervention: LipoNasal n nasal spray (LNM)
Number of subjects: 72
Study 21761190 — intervention group
Group type: EXPERIMENTAL
Intervention: LipoNasal n nasal spray and Tears Again eye spray combination therapy (LTC)
Number of subjects: 72
Study 21761190 — intervention group
Group type: COMPARATOR
Intervention: Standard cromoglycate combination therapy (CGC)
Number of subjects: 72
Study 19842004 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulting a curandero
Number of subjects: 3728
Study 19842004 — intervention group
Group type: EXPERIMENTAL
Intervention: Praying for healing
Number of subjects: 3728
Study 19842004 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking others to pray for healing
Number of subjects: 3728
Study 19842004 — intervention group
Group type: EXPERIMENTAL
Intervention: Considering spiritual healing as very important
Number of subjects: 3728
Study 17227589 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐Linolenic Acid Diet (ALA)
Number of subjects: 23
Study 17227589 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic Acid Diet (LA)
Number of subjects: 23
Study 17227589 — intervention group
Group type: COMPARATOR
Intervention: Average American Diet (AAD)
Number of subjects: 23
Study 17227589 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 23
Study 16002030 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg transdermal nicotine patch
Number of subjects: 20
Study 16002030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11941990 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy
Number of subjects: 0
Study 11941990 — intervention group
Group type: COMPARATOR
Intervention: Acyclic retinoid
Number of subjects: 0
Study 11941990 — intervention group
Group type: COMPARATOR
Intervention: 131I‐lipiodol
Number of subjects: 0
Study 11941990 — intervention group
Group type: COMPARATOR
Intervention: Interferon
Number of subjects: 0
Study 10628024 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultations
Number of subjects: 132
Study 10628024 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient consultation
Number of subjects: 132
Study 1807426 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride mouthwash program
Number of subjects: 0
Study 1807426 — intervention group
Group type: COMPARATOR
Intervention: Control group (students not participating in the fluoride mouthwash program)
Number of subjects: 0
Study 6773156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support, skin protection, and timed surgical intervention
Number of subjects: 63
Study 31068096 — intervention group
Group type: EXPERIMENTAL
Intervention: ComAlong Toddler parental course
Number of subjects: 0
Study 31068096 — intervention group
Group type: COMPARATOR
Intervention: Telephone follow-up
Number of subjects: 0
Study 30776840 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 50
Study 30776840 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 50
Study 30776840 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 50
Study 30776840 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryltrinitrate/Vasopressin
Number of subjects: 50
Study 30776840 — intervention group
Group type: COMPARATOR
Intervention: Control (other vasoactive agents)
Number of subjects: 50
Study 28118559 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (target temperature, 33.0°C)
Number of subjects: 329
Study 28118559 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia (target temperature, 36.8°C)
Number of subjects: 329
Study 28118559 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 329
Study 28118559 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia
Number of subjects: 329
Study 25851383 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical rehabilitation
Number of subjects: 50
Study 25851383 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study 23868855 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivair Nasal Deposition System delivering anhydrous lactose particles (5 μm and 50 μm at doses of 12.5 mg and 25 mg)
Number of subjects: 12
Study 20413454 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 20413454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 18716761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 17
Study 18716761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 17
Study 18716761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 17548440 — intervention group
Group type: EXPERIMENTAL
Intervention: NAb-positive patients during treatment months 0-6
Number of subjects: 468
Study 17548440 — intervention group
Group type: COMPARATOR
Intervention: NAb-negative patients after month 6
Number of subjects: 468
Study 16036030 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (target dosage 25 mg twice daily)
Number of subjects: 3029